The cohort comprised 69 patients with ASS-ILD and 96 patients with PM/DM-ILD, all of whom underwent both spectral CT and conventional high-resolution computed tomography (HRCT). Researchers quantified four types of measurements in each lung lobe: lung volume; 70 keV monoenergetic CT number, abbreviated MCTN; effective atomic number, or Zeff; and electron density, expressed as a percentage of water density. The groups were compared overall and within subgroups matched by radiological pattern or imaging feature, including nonspecific interstitial pneumonia and ground-glass opacity.

A Bonferroni correction was used for multiple testing, with an adjusted significance threshold of p < 0.00625. Across the full comparison, the ASS-ILD group had significantly smaller right- and left-lower-lobe volumes and higher MCTN and electron-density values than the PM/DM-ILD group; all adjusted p values were below 0.05. Volume differences were also observed when the analysis was restricted to patients whose HRCT scans showed nonspecific interstitial pneumonia.

In that subgroup, right-lower-lobe volume in ASS-ILD was 374.79 cm³, with an interquartile range of 291.08 to 619.35 cm³, compared with 596.22 ± 193.33 cm³ in PM/DM-ILD. Left-lower-lobe volume was 364.13 cm³, with an interquartile range of 255.83 to 567.04 cm³, in the ASS-ILD group, versus 563.74 ± 189.98 cm³ in the PM/DM-ILD group. Both raw comparisons produced p values below 0.001.

Quantitative differences also appeared when the researchers selected patients with ground-glass opacity. In that subgroup, left-lower-lobe electron density in ASS-ILD was 29.7% of water density, with an interquartile range of 24.1 to 43.8, compared with 25.3% and an interquartile range of 20.05 to 32.78 in PM/DM-ILD. The corresponding left-lower-lobe MCTN was −706.3 Hounsfield units, with an interquartile range of −763.15 to −562.5, in ASS-ILD, versus −749.7 Hounsfield units and an interquartile range of −802.98 to −678.33 in PM/DM-ILD.

Each ground-glass-opacity comparison had a raw p value of 0.003. These subgroup results show that the measured differences were detectable even when conventional HRCT patterns or signs were similar. Right-lower-lobe volume offered the strongest discrimination among the dual-layer spectral CT parameters evaluated, but its sensitivity of 79.2% and specificity of 58% mean that the measurement alone would not classify every patient correctly.

The study therefore characterizes spectral CT as an adjunct rather than a replacement for conventional HRCT, clinical assessment and serological testing. Within the reported population, however, quantitative lower-lobe differences distinguished ASS-ILD from PM/DM-ILD and demonstrate how spectral CT can add information beyond conventional imaging appearances.

Subject of Research: Diagnostic value of quantitative dual-layer spectral CT for distinguishing ASS-ILD from PM/DM-ILD

Article Title: A quantitative study: investigating the diagnostic value of using dual-layer spectral computed tomography in differentiating idiopathic inflammatory myopathy-associated interstitial lung disease

Article References: Xie, S., Wang, S., Zhang, Z., Liang, Y., Yu, J., Qi, R., Tan, C., Liu, H., Zhang, X., Liao, W., Zhao, L., Zhang, T., & Zhang, L. (2026). A quantitative study: investigating the diagnostic value of using dual-layer spectral computed tomography in differentiating idiopathic inflammatory myopathy-associated interstitial lung disease. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02960-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02960-6

Keywords: spectral CT, antisynthetase syndrome, interstitial lung disease, polymyositis, dermatomyositis, quantitative imaging, lung volume, high-resolution CT, diagnostic accuracy, quantitative, investigating, diagnostic

The therapeutic logic of an ADC is elegantly simple on paper. Each molecule combines three components: a monoclonal antibody that recognizes an antigen displayed on the surface of tumor cells, a chemical linker that holds the assembly together, and a cytotoxic payload far too potent to administer as a conventional drug. After infusion, the ADC circulates in the bloodstream, docks onto its target antigen, and is swallowed whole by the cancer cell through antigen-mediated endocytosis. Inside endosomes and lysosomes, the linker is cleaved and the payload is released, where it kills the cell by disrupting DNA replication or crippling microtubule function. The design goal is selective eradication—chemotherapy-grade killing delivered only to cells bearing the right molecular address, sparing normal tissue from the collateral damage that has defined cytotoxic therapy for decades.

Clinical reality has largely vindicated that concept, at least for a growing list of tumors. Since the U.S. Food and Drug Administration approved the first ADC, gemtuzumab ozogamicin (Mylotarg), in 2000, the field has progressed through three recognizable generations. First-generation conjugates from 2000 to 2012 relied on non-selective linkers and conventional payloads with limited efficacy. The second generation, spanning 2013 to 2019, introduced the linker and payload chemistry that made agents such as trastuzumab emtansine and trastuzumab deruxtecan clinically meaningful. The third generation, from 2020 onward, adds site-specific conjugation, bispecific antibody designs, and immunomodulatory payloads. The pace of approvals has accelerated sharply, and the authors anticipate a continued expansion that will keep reshaping the oncology formulary.

Yet the review is unsparing about who actually benefits. Clinically established ADC targets in solid tumors remain confined to a narrow set of molecules—HER2, TROP2, Nectin-4, folate receptor alpha, tissue factor, and c-MET, with Claudin 18.2-directed agents still investigational. Many membrane proteins and mutated subtypes prevalent in refractory gastrointestinal cancers remain unexplored; KRAS mutations, common in colorectal and pancreatic cancer and associated with poor prognosis, still have no approved ADC directed at them. Compounding the target scarcity is the pronounced intratumoral heterogeneity of solid tumors: within a single lesion, some cell subpopulations express the target abundantly while others show little or none. A single-target ADC may therefore eradicate only a fraction of the tumor, leaving target-negative subclones to seed relapse—and therapeutic pressure actively selects for resistant clones that have downregulated or lost the antigen altogether.

The biomarker problem is, if anything, more disorienting. In theory, the level of target antigen expression should predict response, and in some settings it does: trastuzumab emtansine works best in HER2-high breast cancer, and mirvetuximab soravtansine shows superior efficacy in folate receptor alpha-high, platinum-resistant ovarian cancer. But the correlation repeatedly breaks down. Trastuzumab deruxtecan benefits not only HER2-high patients but also those with HER2-low and, in the defined hormone receptor-positive population, even HER2-ultralow expression. Sacituzumab govitecan and other approved ADCs produce response rates that do not track cleanly with target levels. The authors argue that efficacy is governed by a far more complex biology—epitope accessibility, internalization and recycling kinetics, stromal composition, hypoxia, immune infiltration—and they point to emerging solutions ranging from genomic and transcriptomic profiling to patient-derived organoid assays and machine-learning models that integrate multimodal biomarker data for patient stratification.

Two engineering strategies dominate the search for solutions. The first is multispecificity: bispecific ADCs that recognize two distinct antigens, or two epitopes on the same antigen, can in principle sweep up heterogeneous tumor populations and exploit differential expression between malignant and healthy tissue to concentrate payload at the tumor site. Examples include ZW49, a HER2 biparatopic ADC that has completed a phase I study, and M1231, a MUC1×EGFR bispecific that achieved complete tumor regression in patient-derived xenograft models of non-small cell lung cancer and esophageal cancer. The second is payload diversification. Immune-stimulating antibody conjugates deliver small-molecule agonists—such as activators of the STING pathway—directly to the tumor microenvironment, aiming to ignite local innate immunity while avoiding the systemic toxicity that doomed earlier attempts with TLR7/8 agonists. The review highlights work combining STING activation with TGF-β and PD-L1 blockade, as well as dual-payload ADCs designed to produce additive or synergistic killing from a single molecule.

Sequencing and combination questions are becoming urgent as more patients cycle through multiple ADCs. Four ADCs are now FDA-approved for breast cancer: trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan. Some share antibody backbones, others share payload mechanisms—trastuzumab deruxtecan and sacituzumab govitecan both rely on topoisomerase I inhibition—and accumulating evidence suggests payload-mediated cross-resistance may be a dominant mechanism of acquired resistance. The Translational Breast Cancer Research Consortium is running one prospective registry study and three phase II trials to settle the question. Meanwhile, ADC–immunotherapy combinations have already produced an approved first-line regimen for metastatic urothelial carcinoma, but the disappointing results of pairing trastuzumab deruxtecan with immunotherapy show that rational combination design still requires a much deeper understanding of how individual ADCs remodel the tumor microenvironment.

Safety is the review’s most sobering chapter. A pooled meta-analysis cited by the authors found that treatment-related adverse events occur in more than 90 percent of ADC-treated patients, with 46 percent reaching grade 3 or higher—profiles comparable to, or worse than, conventional chemotherapy. Three agents—belantamab mafodotin, tisotumab vedotin, and mirvetuximab soravtansine—carry FDA boxed warnings for ocular toxicity. In the InnovaTV 204 trial of tisotumab vedotin in cervical cancer, roughly 53 percent of 101 patients experienced ocular adverse events, mostly low-grade conjunctivitis, dry eye, and keratitis, but two developed ulcerative keratitis requiring discontinuation and 22 percent needed dose reductions. Real-world data suggest belantamab-associated ocular toxicity may reach 90 percent in myeloma. The proposed mechanism is unsettling in its simplicity: ADCs accumulate in tears and corneal tissue through Fcγ receptor-mediated uptake by corneal epithelial and limbal stem cells, and the ocular surface’s poor drainage prolongs exposure.

Interstitial lung disease is the other defining hazard. Reported incidence for trastuzumab deruxtecan ranges from 7.6 to 26.4 percent, with some cases progressing to fatal pulmonary injury, and the HER2-targeted candidate ARX788 has shown rates as high as 32.7 percent. No validated pharmacologic prophylaxis exists; management rests on treatment interruption and prompt corticosteroids, with grade 2 or higher pneumonitis mandating permanent discontinuation of trastuzumab deruxtecan. The authors’ own prior work offers a mechanistic clue: alveolar macrophages internalize and process ADCs via Fcγ receptor-mediated phagocytosis, triggering local lung inflammation—an off-target, off-tumor pathway that engineering strategies such as site-specific conjugation, linker stabilization, and antibody masking have so far failed to translate into substantial clinical improvement. ADC development, they note, still leans on trial and error rather than mechanism-guided optimization.

The review closes on a note of ambition rather than resignation. China, which accounts for roughly 43.8 percent of global esophageal cancer cases and 37 percent of gastric cancer cases—against a backdrop of about 4.82 million new cancer diagnoses and 2.57 million cancer deaths in 2022—now hosts the world’s largest clinical pipeline of bispecific ADCs. BL-B01D1, an EGFR×HER3 bispecific developed by Sichuan Baili Pharmaceutical, achieved confirmed objective response rates of 44.1 percent in urothelial carcinoma; Jacobio Pharma’s HER2-targeted STING-agonist conjugate JAB-BX467 is in IND preparation; and Kanghong’s KH815, a dual-payload TROP2-directed ADC delivering both a topoisomerase I and an RNA polymerase II inhibitor, is in first-in-human testing. For the authors, these programs mark China’s transition from fast follower to innovator—and, more broadly, signal that the next generation of ADCs will be judged not by their ability to hit a single target, but by how intelligently they navigate the heterogeneity, biomarker uncertainty, and toxicity that the first two decades of the technology have laid bare.

Subject of Research: Antibody–drug conjugates for solid tumors: mechanisms, clinical landscape, and safety challenges

Article Title: Antibody–drug conjugates in solid tumors: current landscape, challenges, and future directions

Article References: Yang, T., Shimura, T., Wei, Q., & Cheng, X. (2026). Antibody–drug conjugates in solid tumors: current landscape, challenges, and future directions. Holistic Integrative Oncology, 5(1), Article 83. https://doi.org/10.1007/s44178-026-00304-6

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00304-6

Keywords: antibody-drug conjugates, solid tumors, targeted therapy, HER2, interstitial lung disease, ocular toxicity, bispecific antibodies, biomarkers, cancer immunotherapy, payload diversification, China oncology pipeline, drug resistance

The research team, led by pulmonologist Homer L. Twigg III, took advantage of a unique resource: a CLIA-approved clinical bronchoalveolar lavage laboratory that serves clinicians across central Indiana. Bronchoalveolar lavage, or BAL, involves threading a bronchoscope into the airways and instilling saline to wash out cells and soluble proteins from the alveolar spaces, the site where gas exchange occurs. Since October 2020, the laboratory had been receiving BAL fluid from patients undergoing bronchoscopy as part of their clinical work-up for persistent pulmonary symptoms after COVID-19. The only requirement for inclusion in the study cohort was a documented positive SARS-CoV-2 PCR test at some point before the lavage was performed.

By May 2022, the investigators had collected 37 BAL samples from 37 different patients. Five of these were obtained less than 28 days after a positive test and were classified as acute infections, while the remaining 32 were collected between 28 and 730 days after diagnosis, with a median of 178 days. The samples were processed by cytocentrifugation to generate cell differentials, and specimens contaminated with more than 15 percent buccal mucosal or airway epithelial cells were excluded. Two control groups were used for comparison: five healthy volunteers undergoing research bronchoscopy, and seven patients whose clinical BAL samples predated the pandemic entirely.

The cellular analysis revealed that suspected post-COVID-19 lung disease splits into three distinct inflammatory phenotypes. The first was essentially a normal BAL cell differential, with no increase in lymphocytes and minimal neutrophil accumulation. The second was a neutrophilic predominant pattern, defined by neutrophils making up at least 10 percent of the total nucleated cell population and exceeding the lymphocyte fraction. The third was a lymphocytic predominant pattern, in which lymphocytes accounted for at least 15 percent of cells and outnumbered neutrophils. Among the 12 patients with elevated lymphocytes, 8 had markedly inverted CD4-to-CD8 ratios, a finding classically associated with hypersensitivity pneumonitis, nonspecific interstitial pneumonia, chronic viral infections, and cryptogenic organizing pneumonia. The two patients with elevated rather than inverted ratios had underlying conditions, sarcoidosis in one case and mycobacterial antigen-associated hypersensitivity pneumonitis in the other, both known to drive CD4-predominant alveolitis.

Perhaps the most striking result came from the search for viral remnants. Using a commercial ELISA with a sensitivity of 0.256 picograms per milliliter, the team measured SARS-CoV-2 spike protein in acellular BAL fluid. Spike protein was readily detected in unconcentrated lavage fluid from the post-COVID patients compared with controls, and the difference remained significant even after correcting for dilution by expressing concentrations as picograms per milliliter of epithelial lining fluid, calculated using the urea method developed by Rennard and colleagues. Remarkably, spike protein was detected up to 627 days after the initial diagnostic test, supporting the hypothesis that residual viral proteins persist in the lung long after acute infection has cleared. The authors note that expanded data on persistent spike and nucleocapsid proteins, as well as viral nucleic acids, in this same cohort are described in a separate submitted manuscript.

To probe the pulmonary antibody response, the investigators turned to the PepSeq platform, a highly multiplexed serological technique that uses libraries of thousands of DNA-barcoded peptides with next-generation sequencing readout. For these experiments, a human virome-wide assay comprising 15,000 peptides was employed, with samples sequenced to a depth of more than 50 reads per peptide and replicate samples showing a median Z-score concordance of 0.94. Of the first 23 post-COVID subjects tested, 14, or 61 percent, had anti-SARS-CoV-2 antibodies in their BAL fluid, including many with polyclonal responses targeting epitopes on both spike and nucleocapsid proteins. Because the unstructured 30-mer peptides used in PepSeq cannot generally detect antibodies against conformational epitopes, the team also measured neutralizing activity with the cPass assay, which tests the ability of a sample to block binding between spike protein and the ACE2 receptor. Eleven of the 37 BAL samples, or 30 percent, exceeded the assay’s 30 percent inhibition cutoff, while no control sample exceeded 18 percent, and there was complete concordance between neutralizing antibody detection and PepSeq positivity.

The clinical correlations, however, proved more elusive. All subjects underwent chest CT scanning before bronchoscopy, and the scans were reviewed blindly by a NIOSH B Reader radiologist and grouped into predominantly ground glass opacities, predominantly fibrotic or interstitial changes, an equal mixture of both, or other patterns. No clear association emerged between radiographic appearance and the type of inflammatory milieu found in the lung. Long-term outcomes, tracked through chart review as of January 1, 2026, included vital status, need for lung transplant, and need for supplemental oxygen. The BAL inflammatory pattern was unable to predict long-term outcome in this underpowered analysis, although an intriguing signal appeared: no early adverse outcomes were observed among subjects with a normal BAL differential. In unadjusted logistic regression, the odds of a good outcome relative to the neutrophilic pattern were 2.13 for the normal group and 2.24 for the lymphocytic group, with confidence intervals that crossed one.

The findings carry significant implications for how post-COVID-19 lung disease is studied and treated. Because the NASEM definition of long COVID adopted by the NIH RECOVER initiative is purely clinical, relying on symptoms and radiographic findings after documented infection, patients grouped together under that umbrella may in fact harbor fundamentally different processes. The authors suggest that patients with a CD8-predominant lymphocytic pattern may have cryptogenic organizing pneumonia and could respond to corticosteroids, while those with neutrophilic inflammation may have the usual interstitial pneumonia pattern described in surgical lung biopsies of post-COVID patients. Patients with normal lavage fluid, who underwent bronchoscopy because of persistent CT abnormalities, likely have stable scar tissue from their acute infection, which could explain why some post-COVID fibrotic changes fail to progress and may even resolve, echoing the experience after SARS-CoV-1.

The persistence of spike protein also fits into a broader picture of chronic viral antigen stimulation. Prior work has documented residual viral proteins long after other infections, including HIV Nef protein in the lungs of aviremic patients and residual antigen presentation following influenza. Autopsy studies performed a median of 39 days after infection found persistent viral genomic RNA in nearly all patients, and a systematic review detected SARS-CoV-2 RNA in various tissues in 5 to 59 percent of subjects up to six months after acute infection. Persistent antigen can sustain chronic inflammation through multiple mechanisms, including ongoing B and T cell responses, T cell exhaustion and immunosenescence, direct stimulation of macrophages through TLR2, and activation of the complement system, which could plausibly drive the neutrophilic inflammation seen in a third of the patients. Notably, some form of immunosuppression was prevalent in the cohort, affecting 28 of 37 subjects, which the authors suggest may contribute to failure to clear the virus.

The investigators are careful to acknowledge the limitations of their work. The cohort is small and underpowered for linking inflammatory patterns to outcomes, the samples were collected relatively early in the pandemic before widespread vaccination and when more virulent strains circulated, and the cPass 30 percent cutoff was developed for plasma rather than BAL fluid, making the neutralization findings exploratory. There is also no comparison cohort of previously infected patients without chronic lung disease. Still, the study demonstrates that post-COVID-19 lung disease exists in several immunologically distinct forms, that viral proteins can linger in the lung for up to two years, and that clinical presentation alone may be an unreliable guide to the biology underneath. Whether residual SARS-CoV-2 components drive these phenotypes, and whether SARS-CoV-2-specific immune responses can ameliorate the disease, is currently under study.

Subject of Research: Inflammatory and immunologic profiling of bronchoalveolar lavage fluid in patients with post-COVID-19 lung disease

Article Title: Inflammatory and immunologic analysis of bronchoalveolar lavage from patients with post-COVID-19 lung disease

Article References: Twigg, H. L., III, Wilson, R., Yu, A. Q., Li, W., Altin, J. A., Tarver, R. D., Knight, I., Smith, P. A., Fraser, M. E., Castelluccio, P., & Rie, J. (2026). Inflammatory and immunologic analysis of bronchoalveolar lavage from patients with post-COVID-19 lung disease. Frontiers in Microbiology, 17, Article 1923299. https://doi.org/10.3389/fmicb.2026.1923299

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1923299

Keywords: long COVID, post-COVID-19 lung disease, bronchoalveolar lavage, SARS-CoV-2, spike protein, viral persistence, neutralizing antibodies, PepSeq, pulmonary inflammation, interstitial lung disease, alveolar macrophages, immunosenescence

Interstitial lung disease is an umbrella term for more than two hundred disorders in which the delicate tissue between the air sacs becomes inflamed and scarred. As fibrosis accumulates, the lungs stiffen, oxygen transfer falters, and breathlessness deepens. Some patients remain stable for years while others slide rapidly toward respiratory failure, and distinguishing these trajectories early is one of the most urgent unsolved problems in pulmonary medicine. The concept of progressive pulmonary fibrosis was introduced to describe the non-idiopathic pulmonary fibrosis patients whose disease advances despite treatment, and international guidelines now define progression through three domains: worsening respiratory symptoms, declining lung function, and advancing scarring on high-resolution computed tomography.

Because the Xuzhou cohort included both idiopathic pulmonary fibrosis and other fibrotic ILD subtypes, the research team used the term fibrotic disease progression for a progression-like composite outcome adapted from those criteria. Patients were considered progressors if at least two of the three domains worsened within a nine-to-fifteen-month window around the twelve-month follow-up point. Two interstitial lung disease specialists who were blinded to the baseline oscillometry results adjudicated each outcome, and a thoracic radiologist blinded to all physiological data assessed the CT scans. Independent blinding of outcome assessors is a methodological detail that matters enormously in studies like this one, because expectations can otherwise quietly shape how ambiguous changes are judged.

The study was ambispective, meaning it combined retrospectively assembled routine clinical data with prospective follow-up after formal enrollment. Of 348 screened patients, 93 were excluded for reasons including airway-dominant diseases such as COPD and asthma, acute severe illness, malignancy, missing records, or absence of definite fibrosis on baseline CT. The final 255 patients underwent spirometry, diffusing capacity testing and impulse oscillometry at baseline. The technique itself is elegantly simple: while the patient breathes tidally through a mouthpiece, a loudspeaker superimposes small mult-frequency pressure pulses, and the device separates how much of each wave the respiratory system resists, captured as resistance measures R5 and R20, from how elastically it stores and returns energy, captured as reactance X5, resonant frequency Fres and the reactance area AX.

Over the follow-up window, 41 of the 255 patients — 16.1 percent — met the criteria for fibrotic disease progression. At baseline, the progressors already looked mechanically different: their X5 values were more negative, their AX values larger, and their resonant frequencies higher than those of patients who remained stable. By contrast, differences in R20, the resistance measured in larger central airways, were negligible, hinting that the informative signal lives in the lung periphery rather than the conducting airways. When the team modeled each parameter continuously using Firth penalized logistic regression — a method chosen because the number of events was limited and X5 showed near-complete statistical separation — a one-standard-deviation worsening in X5 carried an adjusted odds ratio of 8.89 for subsequent progression, with a confidence interval of 4.66 to 19.47.

AX, a composite measure integrating abnormal reactance across the breathing frequency spectrum, was associated with progression at an adjusted odds ratio of 1.67 per standard deviation, and resonant frequency at 1.61. The resistance measures R5, R20 and the device-reported mean R5–R20 did not survive adjustment and false-discovery-rate correction. Scaled differently, each 0.01 kilopascal-second-per-liter increase in X5, representing a less negative and therefore healthier reactance, was associated with 33 percent lower odds of progression. Yet the story is not a straight line: restricted cubic spline analysis revealed significant nonlinearity, meaning the relationship between X5 and risk changes shape across its range and cannot be compressed into a single constant effect.

The association survived a series of robustness checks. When the 87 patients with idiopathic pulmonary fibrosis were excluded, leaving 168 patients with 28 progression events, X5 remained strongly associated with progression at an adjusted odds ratio of 8.55, and AX stayed significant at 1.47. A sensitivity analysis restricted to patients assessed within a narrower ten-to-fourteen-month window reproduced the same directional pattern. This resilience matters because the formal progressive pulmonary fibrosis construct applies to non-IPF disease, so the signal is not merely an artifact of the most notoriously aggressive fibrotic subtype.

What makes the result scientifically interesting is what X5 and AX actually represent. Although oscillometry is often described as a small-airway test, in fibrotic lung disease the reactance parameters are influenced not only by the caliber of peripheral airways but also by parenchymal stiffness, elastic recoil and the mechanical load of scarred, heterogeneous tissue. In other words, a more negative X5 may reflect the lung as a whole becoming a less compliant, less elastic organ — a direct mechanical signature of fibrosis tightening its grip. Spirometry, the workhorse of pulmonary function testing, requires forceful maximal efforts and mainly indexes larger airways, while oscillometry requires only quiet tidal breathing, which could eventually make it valuable for patients unable to perform demanding maneuvers.

The predictive performance analyses, though explicitly exploratory, were eye-catching. A clinical base model containing age, sex, height and baseline forced vital capacity percent predicted achieved an optimism-corrected area under the curve of only 0.585 — barely better than a coin flip. Adding AX raised it to 0.703, and adding X5, whether modeled linearly or with a spline, lifted it to roughly 0.92, an incremental gain of about 0.34 with confidence intervals comfortably above zero. Brier scores, which penalize prediction error, improved correspondingly. With the internally derived X5 cutoff, no progression events occurred among patients classified as having normal reactance, a complete-separation pattern the authors interpret cautiously as cohort-specific rather than as proof of zero risk.

That caution is warranted, and the researchers are candid about the limitations. The study was conducted at a single center, progression events numbered only 41, and the receiver-operating-characteristic thresholds derived from the data shifted substantially across 500 bootstrap resamples — X5 cutoffs ranged from minus 0.130 to minus 0.050 kilopascal-second per liter — so no clinically applicable cutoff can yet be recommended. Follow-up CT was not uniformly available and was more often obtained in progressors, potentially biasing ascertainment, and treatment changes during follow-up were not modeled. Healthy controls were substantially younger than the patient cohort and served only as a descriptive reference. The authors accordingly frame their conclusions carefully: continuous oscillometric abnormalities, particularly X5 and AX, were associated with subsequent fibrotic progression and merit evaluation in larger, externally validated cohorts, but these results do not yet establish bedside predictive thresholds. If independent teams reproduce the signal, a test that takes minutes and asks nothing more of the patient than relaxed breathing could become a quiet early-warning system for one of medicine’s most relentless disease processes.

Subject of Research: Impulse oscillometry-derived respiratory mechanics as predictors of fibrotic progression in interstitial lung disease

Article Title: Impulse oscillometry-derived respiratory mechanical abnormalities and fibrotic disease progression in interstitial lung disease: a single-center cohort study

Article References: Zhang, C., Wang, Y., Feng, Z., Sun, Y., Zhang, M., Liu, Y., & Chen, B. (2026). Impulse oscillometry-derived respiratory mechanical abnormalities and fibrotic disease progression in interstitial lung disease: a single-center cohort study. Frontiers in Physiology, 17, Article 1962001. https://doi.org/10.3389/fphys.2026.1962001

Image Credits: AI Generated

DOI: 10.3389/fphys.2026.1962001

Keywords: interstitial lung disease, pulmonary fibrosis, impulse oscillometry, X5 reactance, reactance area, respiratory mechanics, progressive pulmonary fibrosis, spirometry, disease progression, lung function testing, Firth penalized regression, predictive modeling

Oscillometry, also called the forced oscillation technique, works by superimposing small, multi-frequency pressure oscillations on a person’s ordinary tidal breathing. Unlike spirometry, which demands forceful, coordinated blows, oscillometry is effort-independent and requires only passive cooperation, making it attractive for children, elderly patients, and people who cannot perform forced maneuvers. The technique reports two fundamental quantities: respiratory resistance, which reflects how hard it is for air to move through the airways, and respiratory reactance, which captures the elastic and inertive properties of the lungs and chest wall. Both are derived from respiratory system impedance, measured across a spectrum of frequencies from 5 to 37 hertz in modern devices.

The Toronto team compared the Tremoflo C-100, made by Thorasys Medical Systems in Canada, with the Resmon Pro, made by Restech srl in Italy. Their cohort of 76 participants included 49 patients with chronic lung disease and 27 healthy volunteers. Among the patients were 37 double-lung transplant recipients, 10 people with interstitial lung disease, one with chronic obstructive pulmonary disease, and one with lymphangioleiomyomatosis. Standard pulmonary function tests classified the group into 36 people with normal lung function, 26 with restriction, 8 with obstruction, and 5 with mixed patterns. Participants completed paired oscillometry with both devices in alternating order, each calibrated daily and performed according to European Respiratory Society technical standards.

The results were unambiguous. For all five primary oscillometry parameters, resistance at 5 hertz (R5), the resistance difference between 5 and 19 hertz (R5-19), reactance at 5 hertz (X5), resonant frequency (Fres), and the area of reactance (AX), the differences between devices reached statistical significance at p at or below 0.001. The Resmon Pro consistently reported lower R5, R5-19, Fres, and AX, and a less negative X5 than the Tremoflo C-100. In practical terms, the Resmon Pro painted a rosier picture of airway mechanics than the Tremoflo did for the same pair of lungs on the same day.

Statistical agreement analysis told a similar story. Intraclass correlation coefficients ranged from 0.59 to 0.85, and Spearman correlations were strong, between 0.779 and 0.920, meaning the devices rank-ordered patients similarly. But correlation is not agreement. Bland-Altman analysis, which plots the difference between paired measurements against their average, revealed systematic bias with wide limits of agreement for every parameter. The bias for AX, a reactance-derived index that integrates the frequency-dependent behavior of reactance, was minus 4.10 centimeters of water per liter, with limits of agreement stretching from minus 14.99 to plus 6.80. For Fres, the limits spanned from minus 6.46 to plus 4.75 hertz. Cohen’s d effect sizes were large for R5, R5-19, X5, and AX, confirming that the differences were not merely statistically detectable but substantively meaningful.

One of the study’s most clinically important findings concerned where the disagreement mattered most. When the researchers applied per-patient Oostveen reference limits, they found that agreement between devices was excellent, 91 to 100 percent within the Bland-Altman limits, when measurements fell within the normal reference range. But when measurements fell outside that range, agreement dropped to 81 to 92 percent. In other words, the systematic bias does little harm when a patient’s lungs are clearly normal, but becomes clinically consequential precisely when the lungs are abnormal, which is when monitoring decisions are being made.

The researchers also tested whether the inter-device differences translated into different patient classifications. They applied two schemes: a two-step decision tree the team had previously developed and validated in over 1,800 patients, and recently published Delphi consensus thresholds for asthma and COPD. Neither device showed clearly superior agreement with the pulmonary-function-test-derived gold standard, with kappa values of roughly 0.30 for the decision tree and only 0.09 to 0.12 for the Delphi thresholds. More concerning, individual participants could be classified differently depending on which device was used, meaning the same patient might be labeled normal by one machine and abnormal by the other.

Why do two devices measuring the same physical quantity disagree so much? The authors point to several technical factors. Hardware differences in oscillation waveform and amplitude can influence the measured signal. The two devices also handle mouthpiece dead space differently and use different calibration procedures: the Tremoflo completes an 8-second calibration against a 15-centimeter-water-second-per-liter reference load, while the Resmon Pro performs an 86-second calibration against a manufacturer-supplied load with distinct resistance and reactance characteristics. Signal processing differs too. The Tremoflo records for 20 seconds with 9 frequencies, while the Resmon Pro records for 60 seconds with 10 frequencies. The longer Resmon recording may improve low-frequency reactance estimation but increases susceptibility to drift and within-test changes in lung mechanics. Tidal volume was also higher during Tremoflo testing in this study.

The study is notable for extending device comparison beyond the healthy volunteers and asthma or COPD populations that dominated earlier work. Prior studies, including work by Dandurand and colleagues using mechanical test loads, Ducharme and colleagues in children, Soares and colleagues with a 3D-printed airway model, and De’s 2026 comparison of the same two devices in 97 symptomatic adults, all found systematic inter-device bias. But the Toronto cohort is the first to directly compare two commercial forced oscillation devices across normal, restrictive, obstructive, and mixed lung function patterns, including patients with interstitial lung disease and stable lung transplant recipients. The restrictive group showed the largest AX discrepancy, with a median Tremoflo value of 13.70 versus 8.23 on the Resmon Pro, a difference the authors note is particularly relevant because reactance abnormalities are the primary oscillometric signature of restrictive disease.

The practical message for clinicians is straightforward: stick with one device when following a patient over time. Changes in oscillometry parameters could otherwise be misattributed to disease progression or treatment response when they actually reflect device-specific differences. The authors also call for standardization of signal generation and processing across manufacturers, which they argue is necessary for cross-device comparability in both clinical practice and multi-center research. Participant feedback added a human dimension: of the 51 people who completed a survey, 61 percent had no preference, but some found the longer Resmon recordings fatiguing, while others preferred the handheld Tremoflo for its easier positioning. As oscillometry moves toward wider clinical adoption, particularly for early detection of lung disease and monitoring of transplant recipients, the Toronto findings make clear that the technology’s promise depends on the field first solving a problem that is less glamorous than the physics itself: getting the machines to speak the same language.

Subject of Research: Agreement between two commercial respiratory oscillometry devices across normal, obstructive, restrictive, and mixed lung function patterns

Article Title: Comparison of two respiratory oscillometers in patients with a broad range of lung function patterns

Article References: Binnie, M., Wu, J. K. Y., & Chow, C.-W. (2026). Comparison of two respiratory oscillometers in patients with a broad range of lung function patterns. Frontiers in Allergy, 7, Article 1896281. https://doi.org/10.3389/falgy.2026.1896281

Image Credits: AI Generated

DOI: 10.3389/falgy.2026.1896281

Keywords: oscillometry, forced oscillation technique, lung function, respiratory resistance, respiratory reactance, Bland-Altman analysis, pulmonary function testing, interstitial lung disease, lung transplant, device standardization, Tremoflo C-100, Resmon Pro

The research, published in BMC Public Health by an extensive network of Italian rheumatologists working with the Systemic Sclerosis Progression Investigation registry under the auspices of the Italian Society of Rheumatology, analyzed 1,795 adult patients with systemic sclerosis. Rather than relying on straight-line map measurements, the team calculated actual driving distances from each patient’s city of residence to their care center using the Google Maps Distance Matrix API, then grouped those distances into standardized classes defined by EUROSTAT, the European Statistical Office. This approach captured the real-world travel burden, including the winding roads and mountain passes that characterize much of the Italian peninsula.

The headline numbers are striking. The median commuting distance was 59.4 kilometers, with an interquartile range running from 38.2 to 101.9 kilometers. More than a quarter of all patients, 25.7 percent, traveled more than 100 kilometers each way to reach the specialists equipped to manage their disease. For a condition that requires frequent monitoring of lung function, blood vessel health, skin thickening, and organ complications, that distance represents a recurring investment of time, money, and physical energy that many patients with a chronic illness can ill afford.

Systemic sclerosis is a multiorgan connective tissue disease characterized by abnormal fibrosis, or scarring, of the skin and internal organs, along with vasculopathy, a dysfunction of the small blood vessels. Its most feared complications include interstitial lung disease, in which scar tissue progressively stiffens the lung tissue, and pulmonary arterial hypertension, a rise in pressure in the arteries supplying the lungs that can lead to heart failure. Both complications are life-limiting, and both demand early detection and specialist management, which is precisely why patients are referred to tertiary centers far from home.

When the researchers cross-referenced travel distance with clinical data, a clear pattern emerged. Patients commuting more than 100 kilometers to their tertiary center presented with more frequent and more severe vascular and fibrotic pulmonary complications than those living closer. Their lung function measures, including forced vital capacity and the diffusion capacity for carbon monoxide, reflected greater impairment. In other words, the patients who had to travel furthest were also, on average, the sickest, and the geography of care access mirrored the geography of disease burden.

The study also examined medication access and pharmaceutical spending, estimating annual drug costs for each patient using standard doses and official prices from the Italian Medicines Agency, known as AIFA. The median annual drug cost came to 4,407 euros per patient. Yet the distribution of spending was highly skewed: just 6.2 percent of patients accounted for half of the total medication budget. This concentration reflects the economics of rare disease treatment, where a small group of patients with severe complications require expensive advanced therapies such as targeted vasodilators and antifibrotic agents.

Perhaps the most intriguing finding concerns the relationship between distance and drug costs. Medication spending clearly reflected clinical manifestations, rising with the severity of lung and vascular disease as expected. But the analysis showed that drug costs correlated with commuting distances independently of disease severity. Patients who traveled farther were more likely to access advanced medications, a pattern the authors suggest may reflect the dynamics of being followed at highly specialized centers, where familiarity with cutting-edge therapies and enrollment in structured care pathways can translate into more aggressive pharmacological management.

The interpretation cuts two ways, and the researchers are careful about what the data can and cannot show. On one hand, longer travel distances may simply be a marker of disease severity, since the most complicated cases are the ones referred to distant expert centers in the first place. On the other hand, the independent association between distance and medication access raises the possibility that proximity to specialized care shapes treatment decisions in ways that go beyond clinical need. Either way, the study demonstrates that geography is not a neutral variable in rare disease management; it is woven into both the presentation of the disease and the response of the health system.

For public health planners, the implications are concrete. The authors argue that strategies should aim to enhance accessibility to specialized care and advanced therapies for systemic sclerosis patients, recognizing the tangible impact of travel burden on healthcare access. Practical measures might include expanding telemedicine follow-up, creating shared-care arrangements in which local hospitals handle routine monitoring while tertiary centers manage complex decisions, and ensuring that patients in remote regions are not systematically disadvantaged in accessing expensive but effective treatments. In a country like Italy, where specialist expertise is concentrated in a limited number of reference centers and the population is dispersed across mountains, islands, and rural interior regions, such structural questions carry real weight.

Beyond systemic sclerosis, the study offers a methodological template for studying other adult-onset rare diseases. By combining registry-based clinical data with algorithmically derived travel distances and standardized cost estimates, the researchers created a quantitative portrait of healthcare commuting that could be replicated for any condition requiring tertiary care. As rare disease networks expand across Europe, the lesson from this Italian cohort is clear: where patients live shapes what care they receive, and health systems that ignore the mileage between the patient and the expert may be quietly tolerating inequities that show up in lungs, blood vessels, and pharmacy bills alike.

Subject of Research: Geographical access to tertiary care and its relationship with disease severity and medication access in systemic sclerosis

Article Title: Travel distance to tertiary healthcare reflects disease severity and medication access in Italian systemic sclerosis patients: a geographical study on adult-onset rare diseases from SPRING-SIR registry

Article References: De Lorenzis, E., Natalello, G., De Angelis, R., Verardi, L., Giuggioli, D., Bajocchi, G., Dagna, L., Bellando-Randone, S., Zanframundo, G., Foti, R., Cacciapaglia, F., Cuomo, G., Ariani, A., Rosato, E., Lepri, G., Girelli, F., Riccieri, V., Zanatta, E., Cavazzana, I., … SPRING-SIR collaborators (2026). Travel distance to tertiary healthcare reflects disease severity and medication access in Italian systemic sclerosis patients: a geographical study on adult-onset rare diseases from SPRING-SIR registry. BMC Public Health. https://doi.org/10.1186/s12889-026-28120-7

Image Credits: AI Generated

DOI: 10.1186/s12889-026-28120-7

Keywords: systemic sclerosis, healthcare access, travel distance, rare diseases, tertiary care, interstitial lung disease, pulmonary arterial hypertension, pharmaceutical costs, health geography, SPRING registry, Italy, telemedicine

The review’s authors systematically mapped six signaling pathways that may fall under interferon-gamma’s influence: JAK/STAT, PI3K/AKT, NF-κB, MAPK, WNT/β-catenin, and the IDO–kynurenine–AhR axis. Crucially, they graded the evidence behind each link, acknowledging that direct mechanistic data in Sjögren’s-associated interstitial lung disease remain scarce. The JAK/STAT pathway, through which interferon-gamma signals via JAK1 and JAK2 to phosphorylate STAT1, carries the strongest support. The intermediate pathways rest on extrapolation from related autoimmune and fibrotic lung diseases, while the WNT and IDO–kynurenine–AhR connections are explicitly labeled exploratory. This candor distinguishes the work from typical mechanistic reviews and provides a roadmap for what must be validated rather than a settled biological hierarchy.

The clinical stakes are considerable. Epidemiologic studies place the prevalence of interstitial lung disease in Sjögren’s patients at 3 to 11 percent, and the histopathological spectrum ranges from nonspecific interstitial pneumonia, the most common pattern, to usual interstitial pneumonia, which a large cohort of 558 patients recently linked to impaired pulmonary function and increased mortality. High-resolution computed tomography typically reveals ground-glass opacities, reticulation, and traction bronchiectasis, while pulmonary function tests show restrictive defects with a disproportionate drop in diffusing capacity. Within the lung, injury to alveolar epithelial type II cells impairs surfactant production and repair, while aberrantly activated fibroblasts deposit extracellular matrix and stiffen tissue, creating the structural context in which interferon-gamma-driven signaling could operate.

Interferon-gamma itself is a type II interferon, structurally distinct from the type I interferons that have long dominated Sjögren’s research. It circulates as a homodimer and engages a tetrameric receptor complex displayed on both immune and non-immune cells. Produced chiefly by activated CD4-positive Th1 cells, CD8-positive T cells, and natural killer cells, the cytokine activates macrophages, licenses dendritic cells by up-regulating MHC molecules and co-stimulatory markers, and steers naïve T cells toward a Th1 fate. It also primes production of tumor necrosis factor-alpha, interleukin-12, and interleukin-1β, and can synergize with toll-like receptor signals to create a self-reinforcing inflammatory loop. In Sjögren’s disease specifically, elevated circulating interferon-gamma has been associated with higher disease activity, and an elevated Th1-to-Th2 ratio correlates significantly with the presence of interstitial lung disease.

The review highlights several mechanisms that could amplify interferon-gamma output in patients. The rs2069705 polymorphism enhances STAT4 binding to the interferon-gamma promoter and increases susceptibility to Sjögren’s disease. Regulatory T cells, which normally restrain Th1 responses, are reduced in both peripheral blood and salivary glands, with the deficit inversely correlating with disease activity as measured by the ESSDAI index. Meanwhile, interferon-responsive chemokines CXCL9, CXCL10, and CXCL11 are sharply up-regulated in serum and salivary gland tissue, potentially recruiting additional CXCR3-expressing T cells into an expanding inflammatory circuit. Recent work also identifies interferon-gamma as a key effector driving salivary gland epithelial cell death and hypofunction, suggesting the cytokine’s pathogenic reach extends beyond immune cells to the structural tissue itself.

At the network level, the proposed model organizes these pathways into layers. Upstream, the interferon-gamma–JAK/STAT axis drives immune-cell activation and chemokine production. In the middle, PI3K/AKT, NF-κB, and MAPK function as amplification and regulatory modules. PI3K/AKT governs immunometabolic reprogramming and B-cell survival, a relevant point given that aberrant B-cell activation and autoantibody production are hallmarks of Sjögren’s pathology, and lupus studies have demonstrated interactions between interferon-gamma signals and PI3K-dependent B-cell responses. NF-κB integrates inflammatory signals and may sustain a pro-inflammatory macrophage state, while MAPK cascades coordinate stress and growth-factor inputs, with experimental evidence linking interferon-gamma-associated p38 and ERK activation to epithelial-to-mesenchymal transition, a pro-fibrotic cellular program.

Downstream, the WNT/β-catenin pathway emerges as the fibrotic executor. Chronic inflammation can switch WNT from a developmental signal into a pathological remodeling program: inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1β, and transforming growth factor-beta influence β-catenin stability, while inflammatory stress represses WNT antagonists, lifting the brakes on the pathway. Across chronic lung diseases, WNT/β-catenin activation correlates with fibroblast proliferation, myofibroblast differentiation, collagen deposition, and tissue stiffness. Altered WNT signaling has been documented in Sjögren’s salivary glands, though its role in the diseased lung remains poorly characterized. The more speculative IDO–kynurenine–AhR axis adds a metabolic layer: sustained interferon-gamma exposure induces indoleamine 2,3-dioxygenase in macrophages and dendritic cells, shunting tryptophan toward kynurenine, which activates the aryl hydrocarbon receptor and reshapes immune tolerance and immune–stromal interactions.

The therapeutic implications are among the most consequential aspects of the framework. Because the JAK/STAT axis carries the strongest evidence, JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib represent the most immediate candidates for modulating interferon-gamma-driven inflammation, particularly in inflammation-dominant disease, although clinical benefit in Sjögren’s-associated interstitial lung disease has not been established. B-cell-directed therapies intersect with the same immune network; real-world data from a multicenter European cohort of 191 patients showed rituximab was used in 25.1 percent of cases, though observational data cannot establish efficacy. For patients who progress to a fibrotic phenotype, the antifibrotic nintedanib, which has demonstrated efficacy in progressive fibrosing interstitial lung diseases across diagnoses, offers a rationale for intervention even though it does not directly target interferon-gamma signaling. The extensive cross-talk among downstream pathways suggests, however, that single-pathway inhibition may prove insufficient for established fibrosis, pointing toward combinatorial, stage-specific strategies.

The authors are careful to frame their model as hypothesis-generating rather than validated. Much of the mechanistic scaffolding derives from associative data, experimental models, or extrapolation from idiopathic pulmonary fibrosis and other connective tissue disease-associated lung diseases. Disease heterogeneity, including variability in immune-cell composition, inflammatory burden, and genetic background, likely shapes which pathways dominate in individual patients. The proposed hierarchy of upstream, intermediate, and downstream modules is explicitly a theoretical synthesis. Prospective validation in longitudinal cohorts, ideally integrating spatial transcriptomics and single-cell profiling, will be required to confirm the temporal sequence and relative contribution of each pathway.

If that validation succeeds, the payoff could be substantial. Biomarkers such as serum CXCL9, CXCL10, KL-6, and even CA125, which a prospective multicenter cohort of 395 patients independently associated with adverse outcomes, could enable patient stratification and disease monitoring aligned with specific pathway activity. More broadly, the review exemplifies a conceptual shift in autoimmune lung disease research: away from linear cytokine cascades and toward multidimensional signaling networks in which immune activation, metabolic reprogramming, and fibrotic remodeling are coupled layers of a single pathogenic architecture. For a disease whose pulmonary complications quietly quadruple mortality risk, that systems-level perspective may finally offer a path toward precision medicine.

Subject of Research: Interferon-gamma-associated signaling networks in Sjögren's disease-associated interstitial lung disease

Article Title: IFN‐γ‐Associated Signaling Networks in Interstitial Lung Disease Associated With Sjögren's Disease

Article References: Chen, Q., Li, Y., Chen, Y., Su, Y., Wang, X., & Guan, C. (2026). IFN‐γ‐Associated Signaling Networks in Interstitial Lung Disease Associated With Sjögren's Disease. Immunity, Inflammation and Disease, 14(10), Article e70547. https://doi.org/10.1002/iid3.70547

Image Credits: AI Generated

DOI: 10.1002/iid3.70547

Keywords: Sjögren's disease, interstitial lung disease, interferon-gamma, JAK/STAT, pulmonary fibrosis, NF-κB, PI3K/AKT, MAPK, WNT/beta-catenin, CXCL10, JAK inhibitors, autoimmunity

The clinical benchmark for staging idiopathic pulmonary fibrosis is the GAP score, an acronym drawn from the variables it incorporates: gender, age, and physiology, the latter captured through lung function tests such as forced vital capacity and the transfer factor for carbon monoxide. The GAP score is a powerful and convenient tool, but it is fundamentally static. It describes the damage that has already accumulated; it says nothing about the biological activity of the disease at the level of the tissue itself. That distinction matters because fibrosis is not merely a passive scar. In active disease, fibroblasts proliferate, inflammatory cells infiltrate, and remodeling processes consume energy, and all of that cellular work demands fuel, principally glucose.

This metabolic hunger is precisely what fluorodeoxyglucose exploits. The radiotracer is a glucose analog labeled with fluorine-18, and once injected it is taken up by metabolically active cells, where it becomes trapped after phosphorylation and emits positrons that the PET scanner detects. In oncology, this principle underpins the familiar maximum standardised uptake value, or SUVmax, a number that quantifies the hottest spot of tracer accumulation within a lesion. The Gdańsk team asked a deceptively simple question: could the same measurement, applied not to tumors but to fibrotic lung parenchyma, serve as a window into the aggressiveness of pulmonary fibrosis?

To find out, the researchers turned to a cohort of thirty patients with idiopathic pulmonary fibrosis who had undergone fluorodeoxyglucose PET/CT for suspected comorbid disease, most often to rule out malignancy. This is a common clinical scenario, since patients with pulmonary fibrosis carry an elevated risk of lung cancer, and the retrospective design allowed the team to mine scans that had already been acquired for other reasons. The researchers measured raw SUVmax values within the fibrotic regions of the lung and compared those values against each patient’s GAP score calculated at the time of the scan. Because uptake values and severity scores are not normally distributed in a sample of this size, they used Spearman’s rank correlation coefficient, a non-parametric statistic that assesses whether two variables tend to increase together without assuming a linear relationship.

The answer was a qualified yes. The correlation between GAP score and fibrotic-lung SUVmax was positive and statistically significant, with a Spearman coefficient of 0.448 and a p-value of 0.013. In plain terms, patients whose lungs burned through more glucose on the scan tended to be the patients whose disease was already more advanced by conventional clinical criteria. A coefficient of 0.448 represents a moderate association, not a perfect one, and the authors are careful to frame the finding as exploratory. Yet the implication is striking: a molecular imaging measurement, taken from a single scan session, appears to carry information that overlaps with, and potentially extends beyond, the physiologic staging that clinicians currently rely upon.

The more provocative part of the study concerns outcomes. The researchers split their cohort into high and low metabolic activity groups using a median split of the SUVmax values, set at 2.53 for the full cohort of thirty patients and at 2.75 for the nineteen patients who were receiving antifibrotic therapy, the modern standard of care with drugs such as the tyrosine kinase inhibitor nintedanib. They then compared progression-free survival and overall survival between the groups using the Mantel-Cox log-rank test, the standard survival analysis method that compares the hazard of an event over time between two populations. In the antifibrotic-treated subgroup, patients with high uptake in their fibrotic lesions showed a median progression-free survival of twenty-five months, exactly half the fifty months observed in the low-uptake group, corresponding to a hazard ratio of 3.68.

Here the statistical caution becomes essential. The confidence interval for that hazard ratio stretched from 0.74 to 18.43, a range that crosses the value of 1.0, meaning the result cannot be distinguished from chance, and the log-rank p-value of 0.089 fell short of the conventional threshold of 0.05. The authors are transparent about this: the survival signal is a hypothesis-generating observation, not a proven predictor. But the pattern is biologically coherent and clinically tantalizing. A hazard ratio approaching four, even with wide uncertainty, suggests that with a larger sample the association could harden into something actionable. If metabolic activity in fibrotic lung truly doubles the pace of progression despite antifibrotic drugs, that information could reshape decisions about monitoring frequency, transplant referral timing, and enrollment into clinical trials of new therapies.

The study’s limitations are the natural consequences of its design. Thirty patients is a small sample, and the scans were acquired for indications unrelated to fibrosis staging, which introduces selection bias even as it offers a glimpse of real-world imaging. The retrospective framework, approved by the Bioethics Committee of the Medical University of Gdańsk with the consent requirement waived, means the researchers could not standardise when or why each scan was performed. SUV measurements are also sensitive to technical factors such as patient blood glucose levels, uptake time, and scanner calibration, all of which complicate comparisons across individuals. The authors themselves conclude that larger prospective studies are required before molecular imaging can be declared an additive prognostic tool in idiopathic pulmonary fibrosis.

Even so, the conceptual advance is worth savoring. For decades, the assessment of fibrotic lung disease has rested on structural and functional endpoints: how much the lung can hold, how well oxygen crosses the membrane, how the tissue looks on high-resolution CT. These measures capture the aftermath of disease. Metabolic imaging, by contrast, offers something closer to a live readout of the pathological process itself, the cellular furnace that drives scarring forward. Previous research has linked fluorodeoxyglucose uptake in the lung to inflammatory and proliferative activity in interstitial disease, and the Gdańsk findings now tie that signal to a validated severity index and to survival trajectories in a treated population.

The road from exploratory correlation to clinical utility is long, and most imaging biomarkers that show promise in small retrospective series never reach the clinic. But the logic of this study points toward a future in which a patient’s PET scan does more than exclude cancer. It could quantify how ferociously their fibrosis is burning, stratify them into risk groups that GAP scores alone cannot resolve, and identify the patients most likely to benefit from intensified therapy or novel antifibrotic agents. For a disease that kills most of those it afflicts within a few years of diagnosis, any tool that reveals the fire beneath the scar, before the lung has irreversibly stiffened, would represent a genuine leap forward. This study is an early, cautious step in that direction, and its authors have mapped the path that the next, larger studies must walk.

Subject of Research: Association between fibrotic-lung FDG-PET uptake and disease severity and outcomes in idiopathic pulmonary fibrosis

Article Title: Association of fibrotic-lung 18F-FDG uptake with GAP severity and clinical outcomes in idiopathic pulmonary fibrosis: an exploratory retrospective study

Article References: Ward, C., Oppmann-Ward, A., Wilczynski, S., Korneliussen, J., Żegleń, S., Rogoza, K., & Cytawa, W. (2026). Association of fibrotic-lung 18F-FDG uptake with GAP severity and clinical outcomes in idiopathic pulmonary fibrosis: an exploratory retrospective study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02856-5

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02856-5

Keywords: idiopathic pulmonary fibrosis, FDG-PET/CT, SUVmax, GAP score, pulmonary fibrosis, nuclear medicine, interstitial lung disease, progression-free survival, antifibrotic therapy, molecular imaging, lung fibrosis, prognosis

The central premise is deceptively simple: early ILD is usually subclinical, producing no symptoms while fibrosis and inflammation silently remodel the pulmonary interstitium. Patients, however, often present to dermatologists early in their disease course with rashes, skin thickening, nailfold changes, or ulcers that precede any respiratory complaint. Because radiographic evidence of ILD frequently appears before pulmonary symptoms develop, the dermatologist’s exam room may be the single best early-warning station for lung disease in this population. The authors argue that dermatologists who understand which skin phenotypes and autoantibody profiles signal elevated pulmonary risk can trigger imaging and referral years before a patient ever reports breathlessness.

The technical backbone of ILD evaluation rests on two pillars: pulmonary function testing (PFTs), including spirometry, lung volumes, and diffusing capacity for carbon monoxide (DLCO), and high-resolution computed tomography (HRCT). HRCT remains the diagnostic gold standard because it detects structural lung abnormalities—ground-glass opacities, reticulation, traction bronchiectasis, and honeycombing—before symptoms arise or before chest radiographs and PFTs become abnormal. Current guidelines broadly recommend against substituting PFTs for HRCT when ILD is suspected, a point underscored by data showing that PFTs alone carry a 62 percent false-negative rate at initial screening for systemic sclerosis-associated ILD. The predominant imaging pattern in most of these diseases is nonspecific interstitial pneumonia (NSIP), although usual interstitial pneumonia (UIP) predominates in systemic vasculitis.

Systemic sclerosis illustrates the stakes most vividly. Recent pooled estimates suggest ILD affects approximately 47 percent of patients with the disease, and lung disease—including pulmonary fibrosis—has now replaced renal crisis as the leading cause of scleroderma-related death. The review emphasizes that dermatologic phenotype is tightly linked to pulmonary risk: patients with diffuse cutaneous disease, in which skin thickening extends proximal to the elbows and knees or onto the trunk, face earlier-onset and more progressive ILD than those with limited cutaneous disease. Anti-topoisomerase I (anti-Scl-70) antibodies mark particularly high risk, while anticentromere antibodies, more typical of limited disease, generally predict lower ILD prevalence. Rarer autoantibodies refine the picture further: anti-Th/To is linked to pulmonary fibrosis and hypertension, anti-U11/U12 RNP to severe fibrosis and increased fibrosis-related mortality, anti-PM/Scl to a myositis-overlap phenotype with high pulmonary fibrosis prevalence, and anti-Ro52 to steeper declines in vital capacity over time.

Screening recommendations for systemic sclerosis are now firm. The American College of Rheumatology and the American College of Chest Physicians recommend that every patient with newly diagnosed disease undergo baseline HRCT and PFTs with DLCO, followed by PFTs every three to twelve months for the first three to five years and at least every six to twelve months thereafter. Short-term progression predicts mortality better than baseline severity, making longitudinal monitoring essential. The OMERACT consensus defines clinically meaningful progression as a relative decline in forced vital capacity of at least 10 percent over one year, or a 5 to 10 percent decline accompanied by a 15 percent or greater drop in DLCO—thresholds associated with increased mortality. Novel low-dose HRCT protocols have demonstrated 88 percent sensitivity and 91 percent accuracy in detecting scleroderma-ILD, and emerging data suggest transthoracic lung ultrasound could serve as a non-ionizing adjunct, though neither has yet replaced standard HRCT in guidelines.

The idiopathic inflammatory myopathies present an even more urgent dermatologic challenge. Myositis-specific autoantibodies (MSAs) powerfully predict organ involvement, and several flag severe pulmonary risk. In antisynthetase syndrome, defined by antibodies against aminoacyl-transfer RNA synthetases, as many as 89 percent of antibody-positive patients show some form of ILD, with anti-PL-7 and anti-PL-12 carriers faring worse than those with anti-Jo-1. Dermatomyositis adds its own red flags: the anti-MDA5 antibody, present in a subset of patients with clinically amyopathic dermatomyositis, is 86 percent specific and 77 percent sensitive for rapidly progressive ILD—a catastrophic subtype that worsens within a month despite high-dose corticosteroids, sends 40 to 60 percent of patients to intensive care, and carries a 45 to 51 percent hospital mortality rate. Painful palmar papules, cutaneous and oral ulceration, elevated ferritin, and lymphocytopenia may all predict this trajectory, and the review is unambiguous that such patients warrant urgent pulmonary evaluation.

The remaining conditions show a spectrum of risk. In systemic lupus erythematosus, ILD prevalence is comparatively low at 1 to 15 percent, and five-year mortality of 14.7 percent is better than in other autoimmune ILDs, but Raynaud’s phenomenon, sclerodactyly, and irregular nailfold capillaries can signal radiographic lung involvement—often reflecting overlap syndromes that must be excluded before attributing risk to lupus alone. Mixed connective tissue disease, defined by high-titer anti-U1 RNP antibodies, carries an ILD prevalence estimated at 34 to 66 percent, and even modest lung involvement on HRCT matters: ten-year survival fell from 87 percent in patients with less than 5 percent lung volume involvement to 60 percent in those with more than 10 percent. Nailfold capillaroscopy, showing enlarged capillaries and scleroderma-pattern changes, may help dermatologists identify MCTD patients who need closer pulmonary scrutiny.

Sjögren’s disease and systemic vasculitis round out the picture. A meta-analysis estimated ILD prevalence at roughly 23 percent in primary Sjögren’s, with cumulative incidence climbing to 20 percent within five years of diagnosis; anti-Ro52 positivity raised prevalence to 41.9 percent versus 16.2 percent in antibody-negative patients, and pooled five-year survival among affected patients was 82 percent. Guidelines from both ERS/EULAR and ACR/CHEST recommend risk-based screening with PFTs and HRCT for patients with features such as older age, male sex, Raynaud phenomenon, lymphopenia, and anti-Ro52 positivity, while explicitly rejecting chest radiography and six-minute walk testing as screening tools. In ANCA-associated vasculitis, ILD prevalence reaches as high as 45 percent in microscopic polyangiitis and 23 percent in granulomatosis with polyangiitis—high enough that ILD was added as a classification criterion for MPA in the 2022 ACR/EULAR guidelines. Notably, no major guideline yet defines evidence-based surveillance intervals for vasculitis-associated ILD, a gap the authors highlight as a priority for future research.

The review’s unifying message is that dermatologists occupy a uniquely powerful position in the multidisciplinary care of these patients. By pairing careful skin examination—recognizing Gottron’s papules, heliotrope rash, mechanic’s hands, shawl and V signs, sclerodactyly, calcinosis, and nailfold changes—with targeted autoantibody testing and a focused review of systems probing dyspnea, cough, and exercise intolerance, dermatologists can stratify risk long before respiratory symptoms emerge. Prompt rheumatology referral remains essential for confirming any suspected systemic autoimmune diagnosis, and pulmonary referral is triggered by symptoms, abnormal PFTs, or HRCT findings. As the authors conclude, familiarity with evidence-based screening and monitoring recommendations, and with the specific cutaneous signatures that demand them, is the key to reducing diagnostic delays and getting patients the antifibrotic and immunosuppressive therapies that increasingly can alter the course of autoimmune lung disease.

Subject of Research: Cutaneous manifestations as risk markers for interstitial lung disease in systemic autoimmune rheumatic diseases

Article Title: Cutaneous manifestations of systemic autoimmune rheumatic diseases including systemic sclerosis, idiopathic inflammatory myopathies, systemic lupus erythematous, mixed connective tissue disease, Sjögren’s disease, and systemic vasculitis and the association with interstitial lung disease: a review of dermatologic risk stratification, screening and monitoring guidelines, and indications for pulmonary referral

Article References: Kirven, R. M., Bogunovich, K., Feibel, A. B., Amigo, M., Trovato, S., Massick, S. C., Allen, J., Ajam, A., & Bechtel, M. A. (2026). Cutaneous manifestations of systemic autoimmune rheumatic diseases including systemic sclerosis, idiopathic inflammatory myopathies, systemic lupus erythematous, mixed connective tissue disease, Sjögren’s disease, and systemic vasculitis and the association with interstitial lung disease: a review of dermatologic risk stratification, screening and monitoring guidelines, and indications for pulmonary referral. Archives of Dermatological Research, 318(1), Article 467. https://doi.org/10.1007/s00403-026-04966-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04966-0

Keywords: interstitial lung disease, systemic sclerosis, dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease, Sjögren's disease, ANCA-associated vasculitis, autoantibodies, HRCT screening, pulmonary function testing, dermatology, autoimmune rheumatic disease

Ocrelizumab is a humanized monoclonal antibody that binds to the CD20 protein found on the surface of B cells, marking them for destruction and dramatically reducing the immune attacks on the nervous system that drive multiple sclerosis. Approved after landmark trials showed clear benefits in both relapsing and primary progressive forms of the disease, it has become one of the most prescribed high-efficacy therapies in neurology. Like all immunotherapies, however, it reshapes the immune system in ways that are still being mapped. Infections, infusion reactions, and a theoretical concern about certain malignancies have long been part of its safety profile. The new study suggests that the lung, an organ densely populated by immune surveillance cells, may occasionally become collateral damage in the altered immunological landscape that follows B-cell depletion.

Organizing pneumonia is not an infection at all, despite its name. It is a form of interstitial lung disease in which the tiny air sacs of the lung and their surrounding tissue become inflamed and then filled with plugs of loose connective tissue, a process pathologists describe as granulation tissue extending into the alveolar spaces. It can arise without any identifiable cause, in which case it is called cryptogenic, or it can be secondary to drugs, infections, radiation, or autoimmune disease. Patients typically develop a persistent fever, a dry cough, and breathlessness that fail to respond to antibiotics, which is precisely the pattern that should alert clinicians to look for something other than bacterial pneumonia. On chest computed tomography, the signature findings are patchy ground-glass opacities, areas of consolidation, and sometimes the striking reversed halo sign, in which a ring of denser tissue surrounds a clearer center.

The Milanese team, led by Enrico Petza and senior author Massimo Filippi, retrospectively collected clinical, radiological, laboratory, treatment, and outcome data from multiple sclerosis patients at their center who developed organizing pneumonia while on ocrelizumab. The five identified patients, three of them women, had a median age of 54 years, with ages ranging from 27 to 64. The condition did not appear early in treatment. On average, patients had been receiving ocrelizumab for about 5.1 years before symptoms emerged, with a standard deviation of 2.9 years, and the lung disease declared itself a mean of 10.8 weeks, with a standard deviation of 10.4 weeks, after the most recent infusion. That long latency is clinically important, because it means neither patient nor physician is likely to connect a fever appearing months after a routine infusion with the drug that caused it.

The clinical picture in all five cases was strikingly uniform. Each patient presented with a persistent fever that refused to yield to antibiotics, and some also had a nonproductive cough. Chest CT scans consistently revealed patchy ground-glass opacities and consolidations, the radiological hallmarks of organizing pneumonia. Treatment followed the standard approach for the condition: all patients received prednisone at doses of 0.5 to 1 milligram per kilogram of body weight per day, continued for a median of 30 days with a range of 15 to 60 days, followed by a gradual tapering of the dose. Corticosteroids suppress the inflammatory process and usually produce a prompt clinical response, and indeed the patients initially improved. Ocrelizumab was discontinued in every case, a decision that reflects the seriousness with which the treating neurologists viewed the association.

The follow-up data, however, reveal a more troubling story than the initial recovery might suggest. Over a median follow-up of 29 months, ranging from 4 to 47 months, four of the five patients experienced respiratory relapses, and residual radiological abnormalities persisted in their lungs despite treatment. Only one patient eventually restarted a disease-modifying therapy, beginning ozanimod, a sphingosine-1-phosphate receptor modulator, two years after the onset of the lung disease. The reluctance to re-expose these patients to immunotherapy is understandable, but it leaves them vulnerable to renewed multiple sclerosis activity, creating a genuine therapeutic dilemma. The persistence of lung changes on imaging also raises questions about whether organizing pneumonia associated with B-cell depletion follows a more indolent course than the idiopathic form of the disease.

To place their five cases in context, the researchers conducted a literature review and identified 17 previously reported cases of organizing pneumonia in ocrelizumab-treated patients. Descriptive comparison showed substantial consistency between the Milanese cohort and the published cases, in terms of timing, presentation, imaging findings, and response to corticosteroids. Earlier reports included patients whose lung disease followed COVID-19 infection during anti-CD20 therapy, complicating the picture, since viral infection itself can trigger secondary organizing pneumonia. But the accumulation of cases without any infectious trigger, occurring years into treatment and weeks after infusions, strengthens the argument that ocrelizumab itself can be the inciting agent. The pattern also echoes what has been described with rituximab, an older anti-CD20 antibody used in lymphoma and rheumatoid arthritis, which has been linked to organizing pneumonia in multiple published reports.

Why would depleting B cells inflame the lung? The authors point out that the mechanism remains unclear and call for further studies to clarify the potential role of CD20-positive lymphocyte depletion in the pathogenesis of organizing pneumonia. Several hypotheses are plausible. B cells are not merely antibody producers; they regulate other immune cells, present antigens, and secrete cytokines that maintain immune homeostasis in tissues. Removing them may disturb the delicate balance of immune surveillance in the lung, allowing aberrant repair processes to take hold. Alternatively, the timing of the lung injury weeks after infusion could reflect the repopulation phase, when immature B cells return and the immune system recalibrates. It is also possible that a subclinical infection, undetected in an immunologically altered host, seeds the inflammatory cascade. Disentangling these possibilities will require immunological studies of affected lung tissue and longitudinal immune monitoring of treated patients.

For clinicians, the practical message is vigilance. A multiple sclerosis patient on ocrelizumab who develops weeks of unexplained fever with a dry cough, especially when antibiotics fail, should undergo chest imaging, and the radiologist should be told to consider organizing pneumonia among the differential diagnoses. Early recognition matters because corticosteroids are effective and because continuing the offending drug may prolong or worsen the lung injury. The authors note that the condition remained rare, affecting fewer than one in a hundred patients at their center, and nothing in the study undermines the substantial efficacy that ocrelizumab has demonstrated in randomized trials. But rare complications of very common drugs translate into real numbers of affected people, and the long latency between treatment and disease makes spontaneous reporting and pooled surveillance essential.

The study also highlights a broader theme in modern neuroimmunology: as high-efficacy immunotherapies transform the prognosis of multiple sclerosis, the frontier of care is shifting toward the fine print of long-term safety. Interstitial lung disease has now been reported as a late occurrence in ocrelizumab-treated patients in other journals as well, suggesting that the signal is no longer anecdotal. Larger registries, systematic pulmonary follow-up, and mechanistic research into how B-cell depletion reshapes lung immunity will be needed to identify who is at risk and whether monitoring or prophylactic strategies can prevent the disease. For now, the Milanese case series offers clinicians a clear template of what to watch for, and it offers patients the reassurance that when the condition is caught, effective treatment exists, even if the road to full recovery can be longer than anyone would like.

Subject of Research: Organizing pneumonia associated with ocrelizumab treatment in multiple sclerosis patients

Article Title: Ocrelizumab-related organizing pneumonia in multiple sclerosis: insights from a case series and literature review

Article References: Petza, E., Guerrieri, S., Marino, V., Gattuso, I., Rubin, M., Nozzolillo, A., Rocca, M. A., Moiola, L., & Filippi, M. (2026). Ocrelizumab-related organizing pneumonia in multiple sclerosis: insights from a case series and literature review. Journal of Neurology, 273(10), Article 600. https://doi.org/10.1007/s00415-026-14130-3

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14130-3

Keywords: multiple sclerosis, ocrelizumab, organizing pneumonia, interstitial lung disease, anti-CD20 therapy, B-cell depletion, corticosteroids, chest CT, drug safety, neuroimmunology, case series, Journal of Neurology